191 related articles for article (PubMed ID: 14676630)
1. Prostate tumor microenvironment alters immune cells and prevents long-term survival in an orthotopic mouse model following flt3-ligand/CD40-ligand immunotherapy.
Ciavarra RP; Holterman DA; Brown RR; Mangiotti P; Yousefieh N; Wright GL; Schellhammer PF; Glass WF; Somers KD
J Immunother; 2004; 27(1):13-26. PubMed ID: 14676630
[TBL] [Abstract][Full Text] [Related]
2. Impact of the tumor microenvironment on host infiltrating cells and the efficacy of flt3-ligand combination immunotherapy evaluated in a treatment model of mouse prostate cancer.
Ciavarra RP; Brown RR; Holterman DA; Garrett M; Glass WF; Wright GL; Schellhammer PF; Somers KD
Cancer Immunol Immunother; 2003 Sep; 52(9):535-45. PubMed ID: 14627125
[TBL] [Abstract][Full Text] [Related]
3. Orthotopic treatment model of prostate cancer and metastasis in the immunocompetent mouse: efficacy of flt3 ligand immunotherapy.
Somers KD; Brown RR; Holterman DA; Yousefieh N; Glass WF; Wright GL; Schellhammer PF; Qian J; Ciavarra RP
Int J Cancer; 2003 Dec; 107(5):773-80. PubMed ID: 14566827
[TBL] [Abstract][Full Text] [Related]
4. Flt3-ligand induces transient tumor regression in an ectopic treatment model of major histocompatibility complex-negative prostate cancer.
Ciavarra RP; Somers KD; Brown RR; Glass WF; Consolvo PJ; Wright GL; Schellhammer PF
Cancer Res; 2000 Apr; 60(8):2081-4. PubMed ID: 10786663
[TBL] [Abstract][Full Text] [Related]
5. Immunity to murine prostatic tumors: continuous provision of T-cell help prevents CD8 T-cell tolerance and activates tumor-infiltrating dendritic cells.
Shafer-Weaver KA; Watkins SK; Anderson MJ; Draper LJ; Malyguine A; Alvord WG; Greenberg NM; Hurwitz AA
Cancer Res; 2009 Aug; 69(15):6256-64. PubMed ID: 19622771
[TBL] [Abstract][Full Text] [Related]
6. Flt3 ligand expands dendritic cell numbers in normal and malignant murine prostate.
Moghaddami M; Swart B; Reynolds P; Diener K; Brown MP
Immunol Cell Biol; 2002 Aug; 80(4):370-81. PubMed ID: 12121227
[TBL] [Abstract][Full Text] [Related]
7. Intratumoral STING Activation with T-cell Checkpoint Modulation Generates Systemic Antitumor Immunity.
Ager CR; Reilley MJ; Nicholas C; Bartkowiak T; Jaiswal AR; Curran MA
Cancer Immunol Res; 2017 Aug; 5(8):676-684. PubMed ID: 28674082
[TBL] [Abstract][Full Text] [Related]
8. CD40 ligand promotes priming of fully potent antitumor CD4(+) T cells in draining lymph nodes in the presence of apoptotic tumor cells.
Fujita N; Kagamu H; Yoshizawa H; Itoh K; Kuriyama H; Matsumoto N; Ishiguro T; Tanaka J; Suzuki E; Hamada H; Gejyo F
J Immunol; 2001 Nov; 167(10):5678-88. PubMed ID: 11698440
[TBL] [Abstract][Full Text] [Related]
9. Simultaneous targeting of CD3 on T cells and CD40 on B or dendritic cells augments the antitumor reactivity of tumor-primed lymph node cells.
Li Q; Grover AC; Donald EJ; Carr A; Yu J; Whitfield J; Nelson M; Takeshita N; Chang AE
J Immunol; 2005 Aug; 175(3):1424-32. PubMed ID: 16034078
[TBL] [Abstract][Full Text] [Related]
10. Combinational FLt3 ligand and granulocyte macrophage colony-stimulating factor treatment promotes enhanced tumor infiltration by dendritic cells and antitumor CD8(+) T-cell cross-priming but is ineffective as a therapy.
Berhanu A; Huang J; Alber SM; Watkins SC; Storkus WJ
Cancer Res; 2006 May; 66(9):4895-903. PubMed ID: 16651446
[TBL] [Abstract][Full Text] [Related]
11. Protective immunosurveillance and therapeutic antitumor activity of gammadelta T cells demonstrated in a mouse model of prostate cancer.
Liu Z; Eltoum IE; Guo B; Beck BH; Cloud GA; Lopez RD
J Immunol; 2008 May; 180(9):6044-53. PubMed ID: 18424725
[TBL] [Abstract][Full Text] [Related]
12. Gene therapy-mediated reprogramming tumor infiltrating T cells using IL-2 and inhibiting NF-κB signaling improves the efficacy of immunotherapy in a brain cancer model.
Mineharu Y; Muhammad AK; Yagiz K; Candolfi M; Kroeger KM; Xiong W; Puntel M; Liu C; Levy E; Lugo C; Kocharian A; Allison JP; Curran MA; Lowenstein PR; Castro MG
Neurotherapeutics; 2012 Oct; 9(4):827-43. PubMed ID: 22996231
[TBL] [Abstract][Full Text] [Related]
13. Dendritic cells in models of tumor immunity. Role of Flt3 ligand.
Maliszewski C
Pathol Biol (Paris); 2001 Jul; 49(6):481-3. PubMed ID: 11484609
[TBL] [Abstract][Full Text] [Related]
14. Anti-tumor effect of the alphavirus-based virus-like particle vector expressing prostate-specific antigen in a HLA-DR transgenic mouse model of prostate cancer.
Riabov V; Tretyakova I; Alexander RB; Pushko P; Klyushnenkova EN
Vaccine; 2015 Oct; 33(41):5386-5395. PubMed ID: 26319744
[TBL] [Abstract][Full Text] [Related]
15. Loss of MyD88 leads to more aggressive TRAMP prostate cancer and influences tumor infiltrating lymphocytes.
Peek EM; Song W; Zhang H; Huang J; Chin AI
Prostate; 2015 Apr; 75(5):463-73. PubMed ID: 25597486
[TBL] [Abstract][Full Text] [Related]
16. An autologous in situ tumor vaccination approach for hepatocellular carcinoma. 2. Tumor-specific immunity and cure after radio-inducible suicide gene therapy and systemic CD40-ligand and Flt3-ligand gene therapy in an orthotopic tumor model.
Kawashita Y; Deb NJ; Garg MK; Kabarriti R; Fan Z; Alfieri AA; Roy-Chowdhury J; Guha C
Radiat Res; 2014 Aug; 182(2):201-10. PubMed ID: 24992166
[TBL] [Abstract][Full Text] [Related]
17. Adenovirus-mediated CD40 ligand therapy induces tumor cell apoptosis and systemic immunity in the TRAMP-C2 mouse prostate cancer model.
Dzojic H; Loskog A; Tötterman TH; Essand M
Prostate; 2006 Jun; 66(8):831-8. PubMed ID: 16491482
[TBL] [Abstract][Full Text] [Related]
18. Fms-Like Tyrosine Kinase 3-Ligand Contributes to the Development and Function of the Subpopulation of CD8α
Huang Y; Xu H; Miller T; Wen Y; Ildstad ST
Stem Cells; 2018 Oct; 36(10):1567-1577. PubMed ID: 30004616
[TBL] [Abstract][Full Text] [Related]
19. NK cells mediate Flt3 ligand-induced protection of dendritic cell precursors in vivo from the inhibition by prostate carcinoma in the murine bone marrow metastasis model.
Tourkova IL; Yamabe K; Chatta G; Shurin GV; Shurin MR
J Immunother; 2003; 26(6):468-72. PubMed ID: 14595214
[TBL] [Abstract][Full Text] [Related]
20. Blockade of the CD40-CD40 ligand pathway potentiates the capacity of donor-derived dendritic cell progenitors to induce long-term cardiac allograft survival.
Lu L; Li W; Fu F; Chambers FG; Qian S; Fung JJ; Thomson AW
Transplantation; 1997 Dec; 64(12):1808-15. PubMed ID: 9422424
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]